WilmerHale Advises Auron Therapeutics in $48 million Series A Financing

WilmerHale Advises Auron Therapeutics in $48 million Series A Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
On July 20, 2022, Auron Therapeutics, a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer, announced the completion of its $48 million Series A financing round. Proceeds will be used to advance the lead program toward clinical development and drive additional programs into drug discovery. Funds will also be used to expand the proprietary, machine learning-based computational platform, AURigin, that is used to identify novel drug targets, and add personnel to support and accelerate research and development.

The WilmerHale deal team advising Auron Therapeutics was led by Cynthia Mazareas and included Elizabeth Brasher and Ornella Ngounou.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel